Sensus Healthcare, Inc. filings document the financial reporting, governance and material-event disclosures of a Nasdaq-listed medical-device company focused on superficial radiotherapy systems for skin conditions. Recent Form 8-K filings furnish quarterly and annual results, non-GAAP reconciliations, business highlights, reimbursement-related disclosures, cash and debt information, and operating updates tied to SRT and IG-SRT systems.
The company’s proxy and governance filings cover annual-meeting matters, director elections, advisory executive-compensation votes, auditor ratification, board composition and independent-director appointments. Other current reports address changes in the independent registered public accounting firm, internal-control disclosures, financial-statement exhibits and related corporate-governance matters.
Sensus Healthcare, Inc. insider Michael Sardano, who serves as President, General Counsel, and a director of the company, reported open-market purchases of SRTS common stock. On 11/11/2025, he bought 1,000 shares of common stock at a price of $4.26 per share, bringing his directly owned holdings to 117,839 shares.
On the same date, his spouse purchased 766 shares at $4.27 per share and 234 shares at $4.34 per share, for a total of 1,000 shares held in the spouse’s name. The filing notes that Sardano disclaims beneficial ownership of the shares held by his spouse.
Sensus Healthcare appointed Eric Sachetta as a Class II director, filling the vacancy created by the passing of William McCall. His term runs until the 2026 annual meeting. The Board determined he is an independent director under Nasdaq Rule 5605(a)(2), and he has been named to the Audit Committee.
Sachetta is Chief Wealth Services Officer of Sachetta, LLC and a Certified Financial Planner. He will receive the same pro rata compensation as other non‑employee directors. The company reported no arrangements or transactions requiring disclosure under Item 404(a).
Sensus Healthcare (SRTS) officer and director Michael Sardano reported open‑market purchases on November 11, 2025.
He acquired 1,000 shares of common stock at $4.26 held directly. Additional purchases were reported for his spouse of 766 shares at $4.27 and 234 shares at $4.24. Following these transactions, Sardano held 117,839 shares directly. He disclaims beneficial ownership of his spouse’s shares. Sardano serves as President and General Counsel and is also a Director.
Sensus Healthcare (SRTS) reported Q3 2025 results showing softer demand and margin pressure. Revenue was $6.9 million, down 21.6% year over year, with gross profit of $2.7 million and a gross margin of 39.1% versus 59.1% a year ago. The quarter recorded a net loss of $0.9 million compared to net income of $1.2 million last year, driven by fewer unit sales and costs tied to a new placement program.
Operating expenses rose as the company increased R&D, marketing, and professional fees. Cash and cash equivalents were $24.5 million as of September 30, 2025, with accounts receivable at $9.3 million and inventories at $13.0 million. One U.S. customer accounted for 59% of quarterly revenue and 86% of accounts receivable. The company’s $15 million revolving credit facility had no borrowings outstanding; on September 26, 2025, the lender waived a default related to a minimum profitability covenant. Shares outstanding were 16,425,036 as of November 5, 2025.
Sensus Healthcare (SRTS) reported an insider stock purchase on Form 4. President and General Counsel, and Director, Michael Sardano bought 1,000 shares of common stock on 11/11/2025 at $4.26 per share.
Following the transaction, he beneficially owned 117,839 shares, held directly. This filing reflects routine insider activity and updates Sardano’s reported ownership position.
Sensus Healthcare, Inc. filed a current report to note that it issued a press release announcing its financial results for the quarter ended September 30, 2025. The company furnished this release as Exhibit 99.1 and incorporated it by reference. The press release includes certain non‑GAAP financial measures, along with reconciliations to the most directly comparable GAAP figures. The information provided under this earnings disclosure section, including Exhibit 99.1, is furnished rather than filed, which affects how it is treated under securities law.
Sensus Healthcare, Inc. completed a Form S-8 registration related to an employee benefit plan, filing corporate governance provisions including indemnification and the company’s ability to purchase insurance for directors and officers. The filing confirms that directors and officers may be indemnified for expenses, including attorneys’ fees, when successful in defense of covered actions, and that such indemnification is in addition to other rights under bylaws or agreements. Signatures from executive officers, including Joseph C. Sardano (Chief Executive Officer) and Javier Rampolla (Principal Financial and Accounting Officer), appear on the document.
Michael Sardano, who serves as a director and as President and General Counsel of Sensus Healthcare, Inc. (SRTS), reported a purchase of 1,000 shares of the company's common stock on 08/13/2025 at a reported price of $3.37 per share. After the transaction, his reported direct beneficial ownership totaled 116,839 shares. The Form 4 lists the transaction code as "P" and shows the change as an acquisition.
Sensus Healthcare reported weakening sales and compressed margins in the quarter and year-to-date. Revenue was $7.3 million in Q2 and $15.7 million for the six months, declines of 20.7% and 21.1% versus prior-year periods driven primarily by fewer units sold to a large U.S. customer. Gross profit fell to $2.9 million in Q2 and $7.3 million YTD, and gross margin narrowed to 39.7% for the quarter (from 58.7%) and 46.5% YTD (from 60.8%).
Higher operating expenses outpaced revenue reductions: G&A, selling and marketing, and R&D all increased, with R&D up 127.8% YTD due to lobbying, added headcount and next-generation product development. The company recorded a net loss of $1.037 million in Q2 and a $3.609 million net loss for the six months, compared with net income in the prior-year periods.
Liquidity remains a stabilizing factor: cash and cash equivalents were $22.2 million and the amended revolving credit facility provides $15.0 million of available borrowing capacity with no outstanding borrowings, and the company was in compliance with credit covenants. Material risks disclosed include significant customer concentration (one U.S. customer represented 56% of Q2 revenue and 78% of receivables) and an ongoing DOJ inquiry for which potential costs cannot be estimated.